A long-term retrospective evaluation (5 years) compares two groups of RDT patients (group 1 on continuous treatment with cellulosic membranes and group 2 with synthetic membranes) regarding survival, general clinical morbidity, and β2M-related morbidity. The results showed no significant long-term differences between the groups either for survival or general morbidity despite some differences in biocompatibility. The higher intradialytic removal of β2M by synthetic membranes did not lead to a reduction in either pre-dialysis β2M values or β2M related morbidity. The higher cost of synthetic over cellulosic membranes and the disappointing of many clinical expectations suggest that the use of such membranes, in association with alternative techniques, should take place only according to certain “elective” indications such as old age, diabetes, vascular instability or intradialytic disequilibrium syndrome.
LowrieE.G., LairdN.M., ParkerT.F., SargentJ.A.. Effect of the hemodialysis prescription on patient morbidity. Report from the National Cooperative Dialysis Study.N Engl J Med1981; 305: 1176.
2.
LaurentG., CalemardE., CharraB.. Dialysis related amyloidosis.Kidney Int1988; 33: 532–4.
3.
TakashiM., SuzukiM., KamimuraA., HirosawaY.. Amyloidosis of a possible new type in patients receiving long-term hemodialysis.Arch Pathol Lab Med1985; 109: 1029–32.
BrownE.A., ArnoldI.R., GowerP.E.. Dialysis arthropathy: complication of long term treatment with hemodialysis.Br Med J1986; 292: 163–6.
6.
BardinT., VasseurM., de VernejoulM.C., JuquelP., ZingraffJ., KuntzD.. Etude prospective de l'atteinte articulaire des malades hémodialysés depuis plus de 10 ans.Rev Rhum1988; 55: 131–4.
7.
StefoniS., FeliciangeliG., ColiL., BonominiV.. Evaluation of a new coated charcoal for hemoperfusion in uremia.Int J Artif Organs1979; 2: 320.
8.
StefoniS., ColiL., FeliciangeliG., BaldratiL., BonominiV.. Regular hemoperfusion in regular dialysis treatment. A long-term study.Int J Artif Organs1980; 3: 348.
9.
BonominiV., StefoniS., FeliciangeliG., ColiL., ScolariM.P.. Shortened treatment time by combined hemodialysis and hemoperfusion.Contr Nephrol1985; 44: 57.
10.
StefoniS., ColiL., FeliciangeliG., ScolariM.P., BonominiV.. Hemoperfusion in reduced time programmes for chronic uremia. Long term results.Int J Artif Organs1986; 9: 297.
11.
StefoniS., Nanni CostaA., Liviano D'ArcangeloG., BiaviatiM., lannelliS., BonominiV.. Biocompatibility of charcoal hemoperfusion. Effects of long-term treatment on lymphocyte characteristics and function.Int J Artif Organs1986; 9: 301.
12.
StefoniS., FeliciangeliG., ScolariM.P.Long-term aspects of blood-material interaction.Life Support Systems, London, Saunders Company Ldt, 1987; 5: 335–40.
13.
StefoniS., Nanni CostaA., lannelliS.Quantitative expression of T-lymphocyte surface antigens in chronic dialysis patients. Biomaterial and clinical applications.Advances in Biomaterials1987; 7: 723.
14.
StefoniS., Nanni CostaA., ColiL.Lymphocyte DNA synthesis and surface antigen expression in chronic dialysis: comparative effects of cuprophan and polysulfone membranes. In: BaldamusC.A., MionC., ShaldonS., eds. Improvements in dialysis therapy. Contrib to Nephrol.Basel: Karger1989; 74: 66–70.
15.
BonominiV.. Introducing the biology of biocompatibility in dialysis.Nephrol Dial Transplant1991; 2: 1–3.
16.
De BroeM.E., NouvenJ., WaeleghemJ.P.. On the mechanisms and site of production of Beta2-microglobulin during hemodialysis.Nephrol Dial Transplant1987; 2: 124–5.
17.
BommerJ., SeelingP., SeelingR., GeelingsW., BommerG., RitzE.. Determinants of plasma B2-m concentration: possible reaction to membrane biocompatibility.Nephrol Dial Transplant1987; 2: 22–5.
18.
StefoniS., Nanni CostaA., lannelliS., FeliciangeliG.Blood-membrane interactions and cellular immunity.Biocybernetics and Biomedical Engineering1991; 11: 51–60.
19.
VincentC., RevillardJ.P., Gal landM., TraegerJ.. Serum Beta-2 microglobulin in hemodialyzed patients.Nephron1978; 21: 260.
20.
ShaldonS., KochK.M., DinarelloC.. Beta2-microglobulin and hemodialysis.Lancet1987; i: 925–6.
21.
GejyoF., HommaN., SuzukiY., ArakawaM.. Serum level of β2M a new form of amyloid protein in patients undergoing long-term hemodialysis.New Engl J Med1986; 314: 585–6.
22.
BardinT., ZingraffJ., ShirahamaT., NoelL.H.. Hemodialysis associated amyloidosis and β2-microglobulin. Clinical and immunohistochemical study.Am J Med1987; 83: 419–24.
23.
BrancaccioD., GallieniM., PadoveseP., AnelliA., CoggiG., UslenghiC.. Dialysis amyloidosis with massive popliteal deposition of β2-microglobulin.Lancet1988; 2: 802.
24.
KronerG., StablerA., SeidererM., MoranJ.E., GurlandD.J.. β2 Microglobulin-related amyloidosis causing atlan toaxial spondylarthropathy with spinal-cord compression in hemodialysis patients; detection by MRI.Nephrol Dialy Transplant Suppl1991; 2: 91–5.
25.
GejyoF., YamadaT., OdaniS.. A new form of amyloid protein associated with chronic hemodialysis was identified as β2M.Biochem Biophys Comm Res1985; 129: 701–6.
